Results 111 to 120 of about 1,978,180 (283)

A single gene mutation predicts response to immune checkpoint blockade in ovarian clear cell carcinoma

open access: yesMolecular Oncology, EarlyView.
Loss‐of‐function mutations in the scaffold subunit of protein phosphatase 2A (PP2A), PPP2R1A, sensitize ovarian clear cell carcinoma to immune checkpoint blockade (ICB) by enhancing the interferon gamma response and promoting antitumor immune cell infiltration.
Matheus Henrique Dias, René Bernards
wiley   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga   +8 more
wiley   +1 more source

Cardiac Biomarkers [PDF]

open access: yesDisease Markers, 2015
Mair, Johannes   +3 more
openaire   +3 more sources

Tumor‐agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell‐free DNA fragmentomics

open access: yesMolecular Oncology, EarlyView.
We evaluated circulating tumor DNA (ctDNA) detection in advanced pancreatic cancer using DNA methylation, cell‐free DNA fragment lengths, and 5′ end motifs. Machine learning models were trained to estimate ctDNA levels from each feature and their combination.
Morten Lapin   +10 more
wiley   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

open access: yesMolecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern   +7 more
wiley   +1 more source

Blood group antigens and integrins as biomarkers in head and neck cancer: Is aberrant tyrosine phosphorylation the cause of altered α6β4 integrin expression? [PDF]

open access: green, 1993
Thomas E. Carey   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy